For Doctors in a Hurry
- Clinicians lack reliable methods to predict future intracranial hemorrhage risk in patients diagnosed with cerebral amyloid angiopathy.
- Researchers followed 109 patients meeting Boston criteria for probable cerebral amyloid angiopathy over a median of 2.93 years.
- Low cerebrospinal fluid amyloid-beta 40 levels were associated with an eightfold increase in incident intracranial hemorrhage (p < 0.001).
- The study concludes that low amyloid-beta biomarkers independently predict symptomatic hemorrhage risk regardless of prior imaging features.
- A composite risk score identified a high-risk subgroup with 78 percent hemorrhage incidence, potentially guiding future clinical management.
Navigating the Hemorrhagic Risks of Cerebral Amyloid Angiopathy
Managing patients with cerebral amyloid angiopathy remains one of the most difficult challenges in vascular neurology, as the condition significantly elevates the risk of spontaneous lobar intracerebral hemorrhage [1]. This risk is particularly acute when patients present with comorbid atrial fibrillation, where the necessity of anticoagulation must be weighed against a high baseline potential for catastrophic bleeding [2]. While recent evidence suggests that left atrial appendage occlusion or carefully selected direct oral anticoagulants may offer some protection, the quality of evidence for these interventions remains limited [3, 4]. Current clinical guidelines emphasize the importance of identifying neuroimaging markers like cortical superficial siderosis to gauge risk, yet these features alone often fail to provide the precision needed for individualized treatment decisions [5, 6]. Furthermore, the presence of white matter hyperintensities and perivascular spaces on magnetic resonance imaging indicates a high burden of small vessel disease but lacks the specificity to predict the timing of future hemorrhagic events [7, 8]. A recent study investigates whether specific biochemical markers in the cerebrospinal fluid can provide the predictive clarity that has long eluded clinical practice.
Quantifying Amyloid Burden in a Clinical Cohort
The researchers conducted a prospective analysis of 109 consecutive patients who met the Boston criteria version 2.0 for probable cerebral amyloid angiopathy, a diagnostic framework that allows clinicians to identify the disease based on specific patterns of cortical hemorrhages and siderosis on magnetic resonance imaging. The study population had a median age of 77 years, and 42% of the participants were female. During the initial diagnostic workup, clinicians obtained cerebrospinal fluid to measure levels of amyloid-beta 40 and 42. In this context, low cerebrospinal fluid levels of these proteins paradoxically indicate higher brain pathology, as the amyloid becomes trapped within the cerebrovascular walls rather than circulating freely, a process that weakens vessel integrity and predisposes patients to rupture. To evaluate the predictive utility of these markers, the study established a primary outcome of incident intracranial hemorrhage, which specifically included lobar intracerebral hemorrhage, convexity subarachnoid hemorrhage, and non-traumatic subdural hemorrhage. The researchers also monitored secondary outcomes to determine if amyloid-beta levels influenced other vascular or survival metrics, specifically tracking ischemic stroke and all-cause mortality. By analyzing these endpoints over a median follow-up period of 2.93 years, the authors aimed to quantify how biochemical evidence of amyloid pathology correlates with the clinical trajectory of patients already showing neuroimaging signs of the disease.
Biomarkers as Independent Predictors of Hemorrhagic Stroke
The researchers monitored the clinical progression of the cohort over a median follow-up period of 2.93 years, with an interquartile range (the middle 50 percent of the data) spanning from 1.43 to 5.03 years. During this observation window, 16 patients (15%) experienced incident intracranial hemorrhage, which served as the primary endpoint of the study. In comparison, 11 patients (10%) experienced incident ischemic stroke. To isolate the predictive value of the biomarkers, the authors utilized multivariate Cox regression models, a statistical method used to determine the independent effect of specific variables on the time it takes for an event to occur. These models were adjusted for disseminated cortical superficial siderosis (blood breakdown products on the brain surface) and prior intracerebral hemorrhage, ensuring that the biomarkers provided prognostic information independent of established neuroimaging markers. The analysis demonstrated that low cerebrospinal fluid amyloid-beta 40 was independently associated with incident intracranial hemorrhage with a hazard ratio of 8.04 (95% CI: 2.43 to 26.59, p < 0.001). Similarly, low cerebrospinal fluid amyloid-beta 42 was independently associated with incident intracranial hemorrhage with a hazard ratio of 7.10 (95% CI: 1.58 to 32.00, p = 0.011). For the practicing physician, these findings indicate that low levels of circulating amyloid proteins are potent indicators of future symptomatic bleeding, even after accounting for the patient's previous hemorrhagic history and current imaging findings.
Stratifying Risk for Clinical Decision Support
The predictive value of these biomarkers appears highly specific to hemorrhagic pathology rather than general vascular decline or systemic frailty. The researchers found that cerebrospinal fluid amyloid-beta biomarkers were not associated with incident ischemic strokes, suggesting that the depletion of these proteins specifically reflects the brittle, hemorrhage-prone state of the cerebral vasculature in amyloid angiopathy rather than a general predisposition to all stroke types. Furthermore, cerebrospinal fluid amyloid-beta biomarkers were not associated with all-cause mortality, indicating that their prognostic utility is centered on specific cerebrovascular events. To translate these biochemical findings into a practical tool for the clinic, the authors developed a composite risk score integrating low cerebrospinal fluid amyloid-beta biomarkers and hemorrhagic imaging features, such as cortical superficial siderosis. This multifaceted approach allows for a more nuanced stratification of patients than imaging or fluid biomarkers could provide in isolation. When applied to the study cohort, this composite risk score identified a high-risk subgroup with a 78% hemorrhage incidence (7 out of 9 patients). Conversely, the same scoring system identified a no-risk group with 0% events (0 out of 42 patients) during the follow-up period. For the practicing physician, this level of risk stratification offers a clearer path for managing complex cases, particularly when weighing the risks and benefits of anticoagulation or antiplatelet therapy. The ability to identify a subgroup with nearly an 80 percent risk of symptomatic bleeding versus a group with no observed events provides a data-driven basis for individualized care. Patients in the high-risk category may require more aggressive blood pressure targets or the avoidance of certain antithrombotic medications, while those in the no-risk group might safely continue necessary therapies for comorbid conditions like atrial fibrillation.
References
1. Samarasekera N, Smith C, Salman RA. The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. Journal of Neurology Neurosurgery & Psychiatry. 2011. doi:10.1136/jnnp-2011-300371
2. Merella P, Casu G, Chessa P, Atzori E, Bandino S, Deiana G. When Atrial Fibrillation Meets Cerebral Amyloid Angiopathy: Current Evidence and Strategies.. Journal of clinical medicine. 2023. doi:10.3390/jcm12247704
3. Mavridis T, Archontakis-Barakakis P, Chlorogiannis D, Charidimou A. Left atrial appendage occlusion in patients with atrial fibrillation and previous Intracranial Hemorrhage or Cerebral Amyloid Angiopathy: A systematic review and meta-analysis.. International journal of stroke : official journal of the International Stroke Society. 2025. doi:10.1177/17474930251360076
4. Chen H, Kakadiya J, Salim HA, et al. Safety and efficacy of anticoagulation for cerebral amyloid angiopathy patients with high-risk atrial fibrillation.. Journal of neurology. 2026. doi:10.1007/s00415-026-13798-x
5. Freund BE, Shourav MMI, Feyissa AM, et al. Seizures in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis.. Neurology. Clinical practice. 2025. doi:10.1212/CPJ.0000000000200454
6. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. European Stroke Journal. 2019. doi:10.1177/2396987319841187
7. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010. doi:10.1136/bmj.c3666
8. Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis. International Journal of Stroke. 2019. doi:10.1177/1747493019830321
